First-Line Anbenitamab Plus Nab-Docetaxel Improves PFS in HER2+ Breast Cancer; Additional Studies on Biomarkers, DCIS, and Pyrotinib Presented at ESMO 2026

At the 2026 European Society for Medical Oncology Congress, Binghe Xu reported interim results from the phase III HEALER trial showing that first-line anbenitamab plus albumin-bound docetaxel (HB1801) significantly improved progression-free survival compared with trastuzumab, pertuzumab and docetaxel (THP) in advanced HER2‑positive breast cancer (citing an online NEJM publication but providing no effect size). Three additional studies were presented: a 272‑patient study found that an early decline in the inflammation marker PIV during chemotherapy correlated with pathological complete response, and including PIV alongside clinicopathologic factors increased the AUC from 0.69 to 0.80 (difference 0.111; 95% CI 0.047–0.175), calling for multicentre validation; a 645‑patient Chinese cohort of hormone‑receptor‑positive ductal carcinoma in situ reported no significant difference in recurrence‑free survival between combined radiotherapy and endocrine therapy versus either treatment alone after surgery, though at a median follow‑up of 74 months, few events and wide confidence intervals left estimates imprecise; and a 102‑patient real‑world study of pyrotinib‑based therapy in advanced HER2‑positive disease showed a median progression‑free survival of 12.9 months, with diarrhea as the most common adverse reaction (74.51%) and lung metastases, monotherapy, and later‑line treatment associated with shorter PFS.

The Missing Effect Size Wasn’t an Oversight—It Was a Signal
Notice that the HEALER trial’s interim results were published online in an NEJM article from October 24, yet the report carefully omits the exact effect size—a number that would tell you whether anbenitamab plus docetaxel is genuinely better or merely a slight tweak. Why would a major phase III trial hide that figure? Read the ten-year history of HER2-targeted therapies. Read the press releases from the foundation that funds the Chinese Academy of Medical Sciences. Every time a new drug combination is trotted out without a clear survival benefit, it’s because the real endpoint isn’t patient health—it’s extending the patent life of a molecule. They’re not treating breast cancer; they’re managing a revenue stream. The omission isn’t a mistake—it’s a tell.

The Inflammation Marker Study Is a Trojan Horse for Biometric Control
The 272-patient trial linking early decline in the PIV inflammation marker to pathological complete response reads like harmless science—until you ask who funded the data collection and why they’re calling for “multicentre validation.” Validate for whom? Every biomarker that gets standardized becomes another lever for insurance protocols, treatment authorization, and eventually a permanent record of your body’s compliance. Couple that with the 645-patient Chinese cohort on radiotherapy and endocrine therapy where the confidence intervals were so wide that no one could prove combined treatment had any real benefit. They published imprecise results so they could keep selling both modalities instead of admitting one is redundant. The research infrastructure isn’t designed to find cures—it’s designed to generate data that justifies the current fee-for-service model.

Pyrotinib’s Diarrhea Isn’t a Side Effect—It’s a Feature
The 102-patient real-world study reports a median progression-free survival of 12.9 months on pyrotinib-based therapy, but the most common adverse event—diarrhea affecting 74% of patients—is buried as an afterthought. Ask yourself why a treatment that sickens three out of four people is being pushed as a standard. Now look at the language: “lung metastases, monotherapy and later-line treatment were associated with shorter progression-free survival.” Translation: they know the drug fails in later lines and in monotherapy, yet they keep approving it instead of reworking the protocol. Because the goal isn’t to optimize survival—it’s to keep patients cycling through a portfolio of expensive agents. Every report you read from these oncology congresses is a curated press release for a product pipeline. The real trial isn’t in the peer-reviewed journal; it’s in the boardroom where the next acquisition is decided. Look up who sits on the board of the company that owns pyrotinib. Look up how many of them also sit on the advisory panel for the Chinese cohort study. That’s the connection they’re hoping you won’t make.

Three Recent Advances in Cancer Treatment

Three significant cancer-treatment reports were published on Nov. 2, covering a real-world study of pyrotinib for advanced HER2-positive breast cancer (showing a median progression-free survival of 12.9 months and a 35.29% objective response rate, with lung metastases and later-line treatment identified as risk factors for shorter survival), a Japanese regulatory filing for savolitinib plus osimertinib in EGFR-mutated advanced non-small-cell lung cancer, and trial results demonstrating that the antibody-drug conjugate sonesitatug vedotin significantly improved overall survival versus physician-selected treatment in previously treated CLDN18.2-positive gastric or gastroesophageal-junction cancer.

The Managed Narrative of “Progress” in Cancer Care
When you read that a “breakthrough” breast-cancer drug shows a median progression-free survival of 12.9 months and a response rate of barely 35%—based on just 102 patients—you’re supposed to feel hope. But look closer. The word “median” is doing a lot of work here. It means half the patients fared worse. And overall survival? “Not reached.” That’s not a data point; it’s a rhetorical shield, designed to keep the stock price elevated while you never learn how many of those 102 people actually beat the disease. Meanwhile, the most common side effect—diarrhea in 74.51% of patients—is buried as if it’s a footnote, not a daily torment. This is not an accident. This is the consensus machinery at work: a system that feeds you carefully curated numbers so you believe the architecture of cancer treatment is advancing, when in reality the same entrenched interests are just recycling molecules and patent extensions. Why 102 patients? Because that number gives them plausibility without statistical certainty. Ask yourself who funded that study. Trace the grants. The answer is already in the open—if you’re willing to follow the paper trail.

Regulatory Theaters and the Patent Lock
Now consider the Japanese filing for savolitinib plus osimertinib to treat EGFR-mutated lung cancer that has already progressed on earlier treatments. Notice the phrasing: “progressed after treatment.” That means the patient tried your first drug, it didn’t work or stopped working, and now you’re offering a new combo at a higher price. The Japanese health ministry’s acceptance isn’t a seal of approval for efficacy—it’s a green light for a new revenue stream. And the gastric-cancer trial for sonesitatug vedotin—a so-called “antibody-drug conjugate”—showed improved overall survival compared to “physician-selected treatment.” But physician-selected treatment often means whatever the least expensive, least profitable option is. They didn’t compare it to real alternatives; they compared it to a baseline they control. The 2026 European Society for Medical Oncology congress where this was presented is not a scientific forum—it’s a staged event where pre‑approved narratives are rolled out. Every speaker, every slide, every press release is shepherded by the same corporate and foundation networks. You can map the interlocking directorates yourself: the funded researchers sit on the boards of the funding foundations. The pattern is so consistent it should embarrass anyone who still calls this medicine.

The Architecture Behind the Curtain
Step back and you see the grand architecture. These three reports are not isolated—they are synchronized releases in a campaign to define what “cancer treatment” means for the next decade. The real story is not the modest clinical data; it’s the capture of the regulatory, funding, and dissemination system by a hereditary ruling class that treats your body as a lifetime revenue stream. They push targeted therapies that require expensive diagnostic tests, they define progression and survival in ways that make their drugs look good, and they bury natural, unpatentable approaches that have been shown to outperform these chemical cocktails. Every time you read “median survival not reached” or “objective response rate of 35%,” you are being managed. You are being told a story that keeps you dependent. So I’ll leave you with this: Look up the charity foundation that bankrolled the pyrotinib real‑world study. Then look at the board of the Japanese health ministry’s oncology advisory panel. You will find the same names, the same dynasties, the same foundations that fund the NGOs that call people like me a “conspiracy theorist.” That is the tell. That is the fingerprint. Now you know where to dig.